Federal Register / Vol. 83, No. 15 / Tuesday, January 23, 2018 / Notices 3155 

3506(c)(2)(A)) requires federal agencies 

to publish a 30-day notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed extension or 

reinstatement of an existing collection 

of information, before submitting the 

collection to OMB for approval. To 

comply with this requirement, CMS is 

publishing this notice that summarizes 

the following proposed collection(s) of 

information for public comment: 

1. Type of Information Collection 

Request: Extension without change of a 

currently approved collection; Title of 

Information Collection: Generic 

Clearance for Questionnaire Testing and 

Methodological Research for the 

Medicare Current Beneficiary Survey 

(MCBS); Use: The purpose of this OMB 

clearance package is to extend the 

approval of the generic clearance to 

support an effort to evaluate the 

operations and content of the Medicare 

Current Beneficiary Survey (MCBS). The 

MCBS is a continuous, multipurpose 

survey of a nationally representative 

sample of aged, disabled, and 

institutionalized Medicare beneficiaries. 

The MCBS, which is sponsored by the 

Centers for Medicare & Medicaid 

Services (CMS), is the only 

comprehensive source of information on 

the health status, health care use and 

expenditures, health insurance 

coverage, and socioeconomic and 

demographic characteristics of the 

entire spectrum of Medicare 

beneficiaries. The core of the MCBS is 

a series of interviews with a stratified 

random sample of the Medicare 

population, including aged and disabled 

enrollees, residing in the community or 

in institutions. Questions are asked 

about enrollees’ patterns of health care 

use, charges, insurance coverage, and 

payments over time. Respondents are 

asked about their sources of health care 

coverage and payment, their 

demographic characteristics, their 

health and work history, and their 

family living circumstances. In addition 

to collecting information through the 

core questionnaire, the MCBS collects 

information on special topics. Form 

Number: CMS–10549 (OMB control 

number 0938–1275); Frequency: 

Occasionally; Affected Public: 

Individuals or Households; Number of 

Respondents: 1,500; Total Annual 

Responses: 1,500; Total Annual Hours: 

1,117. (For policy questions regarding 

this collection contact William Long at 

410–786–7927.) 

Dated: January 18, 2018. 

William N. Parham, III, 

Director, Paperwork Reduction Staff, Office 

of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. 2018–01175 Filed 1–22–18; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Submission for OMB Review; 

Comment Request 

Title: Job Search Assistance (JSA) 

Strategies Evaluation—Extension. 

OMB No.: 0970–0440. 

Description: The Administration for 

Children and Families (ACF), is 

proposing the extension without 

changes to an existing data collection 

activity as part of the Job Search 

Assistance (JSA) Strategies Evaluation. 

The JSA evaluation will aim to 

determine which JSA strategies are most 

effective in moving TANF applicants 

and recipients into work and will 

produce impact and implementation 

findings. To date, the study has 

randomly assigned individuals to 

contrasting JSA approaches. The study 

will next compare participant 

employment and earnings to determine 

the relative effectiveness of these 

strategies. The project will also report 

on the implementation of these 

strategies, including measures of 

services participants receive under each 

approach, as well as provide operational 

lessons gathered directly from 

practitioners. 

Data collection efforts previously 

approved for JSA, include: Data 

collection activities to document 

program implementation, a staff survey, 

a baseline information form for program 

participants, and a follow-up survey for 

JSA participants approximately 6 

months after program enrollment. 

Approval for these activities expires on 

February 28, 2018. 

This Federal Register Notice provides 

the opportunity to comment on the 

extension of the 6-month follow-up 

survey to allow follow-up data to be 

collected for all study participants. 

Although the enrollment period was 

originally estimated to span 12 months, 

it took 18 months to complete 

enrollment, leaving insufficient time to 

complete the 6-month follow-up survey. 

A four-month extension is requested in 

order to allow individuals randomly 

assigned between June and August 2017 

to complete the follow-up survey in the 

same timeframe as earlier enrollees. The 

purpose of the survey is to follow-up 

with study participants and document 

their job search assistance services and 

experiences including their receipt of 

job search assistance services, their 

knowledge and skills for conducting a 

job search, the nature of their job search 

process, including tools and services 

used to locate employment, and their 

search outputs and outcomes, such as 

the number of applications submitted, 

interviews attended, offers received and 

jobs obtained. In addition, the survey 

will provide an opportunity for 

respondents to provide contact data for 

possible longer-term follow-up. There 

are no changes to the currently 

approved instruments. 

Respondents: JSA study participants. 

Annual Burden Estimates: This 

extension is specific to the 6-month 

survey and covers the remaining 766 

participants that may be completing the 

six-month follow up survey during the 

four-month extension period. All other 

information collection under 0970–0440 

will be complete by the original OMB 

expiration date of February 28, 2018. 

Instrument 

Total/annual 

number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden hours 

per response 

Annual 

burden hours 

Extension of Previously Approved Information Collection 

6-Month Follow-Up Survey .............................................................................. 766 1 .333 255 

Estimated Total Annual Burden 

Hours: 255. 

Additional Information: Copies of the 

proposed collection may be obtained by 

writing to the Administration for 

Children and Families, Office of 

Planning, Research and Evaluation, 330 

C Street SW, Washington, DC 20201, 

Attn: OPRE Reports Clearance Officer. 

All requests should be identified by the 

title of the information collection. Email 

address: OPREinfocollection@

acf.hhs.gov. 

OMB Comment: OMB is required to 

make a decision concerning the 


sradovich on DSK3GMQ082PROD with NOTICES
3156 Federal Register / Vol. 83, No. 15 / Tuesday, January 23, 2018 / Notices 

collection of information between 30 

and 60 days after publication of this 

document in the Federal Register. 

Therefore, a comment is best assured of 

having its full effect if OMB receives it 

within 30 days of publication. Written 

comments and recommendations for the 

proposed information collection should 

be sent directly to the following: Office 

of Management and Budget, Paperwork 

Reduction Project, Email: OIRA_

SUBMISSION@OMB.EOP.GOV. Attn: 

Desk Officer for the Administration for 

Children and Families. 

Mary Jones, 

ACF/OPRE Certifying Officer. 

[FR Doc. 2018–01140 Filed 1–22–18; 8:45 am] 

BILLING CODE 4184–09–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2018–N–0045] 

Pediatric Advisory Committee and the 

Endocrinologic and Metabolic Drugs 

Advisory Committee; Notice of 

Meeting; Establishment of a Public 

Docket; Request for Comments 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; establishment of a 

public docket; request for comments. 

SUMMARY: The Food and Drug 

Administration (FDA) announces a 

forthcoming public advisory committee 

meeting of the Pediatric Advisory 

Committee (PAC) and the 

Endocrinologic and Metabolic Drugs 

Advisory Committee (EMDAC). At least 

one portion of the meeting will be 

closed to the public. The general 

function of the committees is to provide 

advice and recommendations to FDA on 

regulatory issues. FDA is establishing a 

docket for public comments on this 

document. 

DATES: The meeting will be held on 

March 22, 2018, from 8:30 a.m. to 5:30 

p.m. 

ADDRESSES: FDA White Oak Campus, 

10903 New Hampshire Ave., Building 

31 Conference Center, the Great Room 

(Rm. 1503), Silver Spring, MD 20993– 

0002. Answers to commonly asked 

questions including information 

regarding special accommodations due 

to a disability, visitor parking, and 

transportation may be accessed at: 

https://www.fda.gov/Advisory

Committees/AboutAdvisoryCommittees/ 

ucm408555.htm. 

FDA is establishing a docket for 

public comment on this meeting. The 

docket number is FDA–2018–N–0045. 

The docket will close on March 23, 

2018. Submit either electronic or 

written comments on this public 

meeting by that date. Please note that 

late, untimely comments will not be 

considered. The https://

www.regulations.gov electronic filing 

system will accept comments until 

midnight Eastern Time at the end of 

March 23, 2018. Comments received by 

mail/hand delivery/courier (for written/ 

paper submissions) will be considered 

timely if they are postmarked or the 

delivery service acceptance receipt is on 

or before that date. 

Comments received on or before 

March 8, 2018, will be provided to the 

committee. Comments received after 

that date will be taken into 

consideration by FDA. 

You may submit comments as 

follows: 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include Docket No. FDA–2018–N– 

0045 for ‘‘Pediatric Advisory Committee 

and the Endocrinologic and Metabolic 

Drugs Advisory Committee; Notice of 

Meeting; Establishment of a Public 

Docket; Request for Comments.’’ 

Received comments, those filed in a 

timely manner (see ADDRESSES), will be 

placed in the docket and, except for 

those submitted as ‘‘Confidential 

Submissions,’’ publicly viewable at 

https://www.regulations.gov or at the 

Dockets Management Staff between 9 

a.m. and 4 p.m., Monday through 

Friday. 

• Confidential Submissions—To 

submit a comment with confidential 

information that you do not wish to be 

made publicly available, submit your 

comments only as a written/paper 

submission. You should submit two 

copies total. One copy will include the 

information you claim to be confidential 

with a heading or cover note that states 

‘‘THIS DOCUMENT CONTAINS 

CONFIDENTIAL INFORMATION.’’ FDA 

will review this copy, including the 

claimed confidential information, in its 

consideration of comments. The second 

copy, which will have the claimed 

confidential information redacted/ 

blacked out, will be available for public 

viewing and posted on https://

www.regulations.gov. Submit both 

copies to the Dockets Management Staff. 

If you do not wish your name and 

contact information be made publicly 

available, you can provide this 

information on the cover sheet and not 

in the body of your comments and you 

must identify the information as 

‘‘confidential.’’ Any information marked 

as ‘‘confidential’’ will not be disclosed 

except in accordance with 21 CFR 10.20 

and other applicable disclosure law. For 

more information about FDA’s posting 

of comments to public dockets, see 80 

FR 56469, September 18, 2015, or access 

the information at: https://www.gpo.gov/ 

fdsys/pkg/FR-2015-09-18/pdf/2015- 

23389.pdf. 

Docket: For access to the docket to 

read background documents or the 

electronic and written/paper comments 

received, go to https://

www.regulations.gov and insert the 

docket number, found in brackets in the 

heading of this document, into the 

‘‘Search’’ box and follow the prompts 

and/or go to the Dockets Management 

Staff, 5630 Fishers Lane, Rm. 1061, 

Rockville, MD 20852. 

FOR FURTHER INFORMATION CONTACT: 

Marieann Brill, Office of the 

Commissioner, Food and Drug 


sradovich on DSK3GMQ082PROD with NOTICES